Literature DB >> 30937942

Evaluation of the Performance of the Ultrasound (US) Elastographic Q-Analysis Score Combined With the Prostate Imaging Reporting and Data System for Malignancy Risk Stratification in Prostate Nodules Based on Transrectal US-Magnetic Resonance Imaging Fusion Imaging.

Zhimin Ding1, Xiuqin Ye1, Lei Zhang1, Yu Sun1, Zhipeng Ni1, Huiyu Liu1, Jinfeng Xu1, Fajin Dong1.   

Abstract

OBJECTIVES: This study retrospectively evaluated the prognostic performance of the ultrasound elastographic Q-analysis score (EQS) combined with the Prostate Imaging Reporting and Data System (PI-RADS) for malignancy risk stratification in prostate nodules based on transrectal ultrasound-magnetic resonance imaging fusion imaging.
METHODS: Sixty-two patients who were suspected to have PCa between October 2017 and May 2018 in our hospital were retrospectively evaluated. The performance of the EQS and PI-RADS was evaluated by patients' receiver operating characteristic curves in differentiating malignant and benign prostate nodules. The combination of the EQS and PI-RADS methods for prostate imaging was evaluated.
RESULTS: Sixty-two prostate nodules in 62 patients were included. All of the patients underwent biopsy; 29 cases were prostate cancer, and the rest were benign prostate lesions. Both the EQS and PI-RADS were significantly higher in malignant nodules than in benign nodules. The sensitivity, specificity, area under the curve, positive likelihood ratio, negative likelihood ratio, positive predictive value, negative predictive value, and Youden index of an EQS cutoff of 2.05 were 86.2%, 81.8%, 85.9%, 4.73, 0.169, 80.6%, 87.1%, and 68%, respectively. The corresponding numbers for a PI-RADS cutoff of 4 were 82.7%, 69.7%, 84.2%, 2.72, 0.25, 70.6%, 82.1%, and 52.4%. The "tandem" method had a higher diagnostic specificity (87.9%), positive likelihood ratio (6.55), and positive predictive value (85.1%). The "parallel" method had a higher diagnostic sensitivity (96.5%), negative likelihood ratio (0.06), and negative predictive value (95.2%).
CONCLUSIONS: both the EQS and PI-RADS had good diagnostic performance in differentiating between malignant and benign prostate lesions. The combination of the EQS and PI-RADS improved the diagnostic performance to a certain degree.
© 2019 by the American Institute of Ultrasound in Medicine.

Entities:  

Keywords:  Prostate Imaging Reporting and Data System; diagnostic performance; elastographic Q-analysis score; parallel; prostate biopsy; prostate nodules; tandem; ultrasound

Mesh:

Year:  2019        PMID: 30937942     DOI: 10.1002/jum.15005

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  4 in total

1.  Assessment of elastographic Q-analysis score combined with Prostate Imaging-Reporting and Data System (PI-RADS) based on transrectal ultrasound (TRUS)/multi-parameter magnetic resonance imaging (MP-MRI) fusion-guided biopsy in differentiating benign and malignant prostate.

Authors:  Hongtian Tian; Zhimin Ding; Huaiyu Wu; Keen Yang; Di Song; Jinfeng Xu; Fajin Dong
Journal:  Quant Imaging Med Surg       Date:  2022-07

2.  Development and validation of a nomogram for predicting prostate cancer in men with prostate-specific antigen grey zone based on retrospective analysis of clinical and multi-parameter magnetic resonance imaging/transrectal ultrasound fusion-derived data.

Authors:  Zhimin Ding; Huaiyu Wu; Di Song; Hongtian Tian; Xiuqin Ye; Weiyu Liang; Yang Jiao; Jintao Hu; Jinfeng Xu; Fajin Dong
Journal:  Transl Androl Urol       Date:  2020-10

3.  Development and validation of a nomogram based on multiparametric magnetic resonance imaging and elastography-derived data for the stratification of patients with prostate cancer.

Authors:  Zhimin Ding; Di Song; Huaiyu Wu; Hongtian Tian; Xiuqin Ye; Weiyu Liang; Jinfeng Xu; Fajin Dong
Journal:  Quant Imaging Med Surg       Date:  2021-07

Review 4.  Alternatives for MRI in Prostate Cancer Diagnostics-Review of Current Ultrasound-Based Techniques.

Authors:  Adam Gurwin; Kamil Kowalczyk; Klaudia Knecht-Gurwin; Paweł Stelmach; Łukasz Nowak; Wojciech Krajewski; Tomasz Szydełko; Bartosz Małkiewicz
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.